FDA approves Velcade for the initial treatment of patients with Multiple Myeloma

ASCO SIGN IN

Manage Email Subscriptions

Username:

Create an account

Why Be A Member?

Password:

Remember me

Forgot your username or password?

ASCO Membership Directory

The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

ASCO Home

Practice & Guidelines

Practice Management & Reimbursement

FDA Drug Alerts

FDA approves Velcade for the initial treatment of patients with Multiple Myeloma

On June 20, 2008, the U.S. Food and Drug Administration approved bortezomib for injection (Velcade®, Millennium Pharmaceuticals, Inc., The Takeda Oncology Company, and Johnson and Johnson Pharmaceutical Research and Development) for the treatment of patients with multiple myeloma. This approval results from a clinical trial using Velcade® as an initial treatment for patients with multiple myeloma. Velcade® was previously approved in 2005 for the treatment of patients with multiple myeloma who had received at least one prior therapy and in 2003 for the treatment of more refractory multiple myeloma.

The current approval was based on an international, multicenter, open label, active-control trial in previously untreated patients with symptomatic multiple myeloma. Patients were randomized to receive either nine 6 week cycles of oral melphalan (M) plus prednisone (P), or MP plus bortezomib. Patients received M (9 mg/m2) plus prednisone (60 mg/m2) daily for four days every 6 weeks or the same MP schedule with bortezomib, 1.3 mg/m2 iv on days 1, 4, 8, 11, 22, 25, 29, and 32 of every 6 week cycle for 4 cycles then once weekly for 4 weeks on days 1, 8, 22 and 29 of every 6 week cycle for 5 additional cycles. Time-to-progression (TTP) was the primary efficacy endpoint. Overall survival (OS), progression-free survival (PFS), and response rate (RR) were secondary endpoints. The majority of the patients enrolled were â‰¥ 65 years of age. A total of 682 patients were randomized: 338 to receive MP and 344 to receive the combination of bortezomib plus MP. Demographics and baseline disease characteristics were similar between the two groups.

The trial was stopped following a pre-specified interim analysis showing a statistically significant improvement in TTP with the addition of bortezomib to MP (median 20.7 months) compared with MP (median 15 months) [HR: 0.54 (95% CI: 0.42, 0.70), p= 0.000002]. OS, PFS, and RR also were significantly superior for the bortezomib-MP combination.

The most common adverse reactions (incidence â‰¥30%) in clinical studies of bortezomib include asthenic conditions, diarrhea, nausea, constipation, peripheral neuropathy, vomiting, pyrexia, thrombocytopenia, psychiatric disorders, anorexia and decreased appetite, neutropenia, neuralgia, leukopenia and anemia. Dose adjustment guidelines for hematologic and neurologic toxicity are detailed in the label (package insert).

Full prescribing information, including clinical trial information, safety, dosing, drug-drug interactions and contraindications is available at the FDA Website.